PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling Pathways

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 expression, resulting in poor prognosis and limited therapeutic options.
• Aberrant molecular signaling pathways are critical drivers of cancer development, necessitating the identification of novel therapeutic targets.
• PIM kinase is frequently overexpressed in TNBC and other cancers, playing a vital role in cell proliferation and survival, making it an attractive drug target.

Purpose of the Study:

• To review the current understanding of the PIM-STAT3 signaling axis in the context of triple-negative breast cancer.
• To explore the therapeutic potential of targeting PIM1 and STAT3, individually or in combination, for TNBC treatment.

Main Methods:

• Literature review focusing on the PIM-STAT3 signaling pathway and its role in cancer.
• Analysis of existing research on PIM kinase and STAT3 signaling in triple-negative breast cancer.
• Identification of potential therapeutic strategies involving PIM1 and STAT3 inhibitors.

Main Results:

• The PIM-STAT3 axis is implicated in the progression and transformation of TNBC.
• PIM1 is a downstream target of the STAT3 signaling pathway, and their interplay is crucial for cancer cell survival.
• Inhibitors targeting PIM1 and STAT3 demonstrate potential as anticancer agents.

Conclusions:

• The PIM-STAT3 axis represents a promising therapeutic target for triple-negative breast cancer.
• Developing PIM1 and STAT3 co-inhibitors could offer a novel strategy for TNBC treatment.
• Further research into the PIM-STAT3 axis may lead to the development of effective anticancer agents for TNBC.